Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit

An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Anne Rain Tanner, Horng, Michelle, Shigle, Terri Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189427/
http://dx.doi.org/10.1007/978-3-319-74588-6_23
_version_ 1783527493258444800
author Brown, Anne Rain Tanner
Horng, Michelle
Shigle, Terri Lynn
author_facet Brown, Anne Rain Tanner
Horng, Michelle
Shigle, Terri Lynn
author_sort Brown, Anne Rain Tanner
collection PubMed
description An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effects. This chapter will provide clinicians with an overview of non-chemotherapy medications frequently encountered in the critically ill oncologic patient, with a focus on practical considerations.
format Online
Article
Text
id pubmed-7189427
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71894272020-04-29 Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit Brown, Anne Rain Tanner Horng, Michelle Shigle, Terri Lynn Oncologic Critical Care Article An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effects. This chapter will provide clinicians with an overview of non-chemotherapy medications frequently encountered in the critically ill oncologic patient, with a focus on practical considerations. 2019-07-09 /pmc/articles/PMC7189427/ http://dx.doi.org/10.1007/978-3-319-74588-6_23 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Brown, Anne Rain Tanner
Horng, Michelle
Shigle, Terri Lynn
Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title_full Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title_fullStr Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title_full_unstemmed Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title_short Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit
title_sort considerations for medications commonly utilized in the oncology population in the intensive care unit
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189427/
http://dx.doi.org/10.1007/978-3-319-74588-6_23
work_keys_str_mv AT brownanneraintanner considerationsformedicationscommonlyutilizedintheoncologypopulationintheintensivecareunit
AT horngmichelle considerationsformedicationscommonlyutilizedintheoncologypopulationintheintensivecareunit
AT shigleterrilynn considerationsformedicationscommonlyutilizedintheoncologypopulationintheintensivecareunit

Ejemplares similares